Dr. Varsha Rao is the Director of Partnerships and Clinical Affairs at ClaretBio. She oversees the clinical applications of the novel next-generation sequence assays and analytical pipelines developed at ClaretBio with a main focus on evaluating the utility of cell-free DNA fragmentation patterns in cancer progression and treatment response monitoring. Before joining ClaretBio, she was a Research Scientist at Stanford University School of Medicine in Prof Michael Snyder’s lab. As a part of multiple consortia such as the Integrative Personalized Omics Profiling Project, the Human Microbiome Project and the NASA Twins Study she has worked on longitudinal multiomic analyses, focusing on applying transcriptomics and liquid biopsy approaches to understand nuances of metabolic diseases, cancer, infectious disease and general health. She received her PhD in Molecular and Cellular Biology from University of Maryland Baltimore County in 2012.
Clinical Dx Showcase:
Claret Bioscience's mission is to improve the quality of NGS data obtained from degraded, highly fragmented, and low yield samples. Our approach aims to provide a complete picture of DNA molecules, enhancing the sensitivity of disease screenings, and ultimately improving treatment decisions.
Getting the complete story - cfDNA fragmentomics
Capturing cfDNA fragmentation information can potentially enable clinical diagnoses at low depth of sequencing.
Track Chair: Cindy Perettie, Roche